Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01433523Phase 3Completed

House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma

Role: collaborator

NCT01425788Phase 2Completed

Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense

Role: collaborator

NCT00668850Phase 3Unknown

Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin

Role: collaborator

All 3 trials loaded